Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

c-erbB-2 as a target for immunotherapy.

S Eccles1

  • 1Section of Cancer Therapeutics, McElwain Laboratories, Institute of Cancer Research, Cotswold Rd., Belmont, Sutton, Surrey, SM2 5NG, UK.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Forced treadmill exercise in the male rat: effect on food intake and c-Fos expression.

Physiology & behavior·2025
Same author

Less than full time training in plastic surgery: A qualitative survey-based study and practical suggestions for improvement.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2022
Same author

Painful exostosis of the external occipital protuberance.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2015
Same author

Risk factors for alloimmunisation in the general patient population.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2015
Same author

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10.

British journal of cancer·2012
Same author

Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival.

British journal of cancer·2007

The c-erbB-2 oncoprotein, a target for cancer immunotherapy, drives tumor invasion and metastasis. Immunotherapeutic strategies, including vaccines and monoclonal antibodies, show safety and potential efficacy in clinical trials for advanced cancers.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The c-erbB-2 proto-oncogene encodes a tyrosine kinase receptor (p185) implicated in poor cancer prognosis.
  • Overexpression of c-erbB-2 is linked to tumor invasion, metastasis, and resistance to conventional therapies.
  • Its cell surface expression and limited presence in normal tissues make c-erbB-2 an attractive target for immunotherapy.

Purpose of the Study:

  • To review the potential of c-erbB-2 as a target for cancer immunotherapy.
  • To discuss various immunotherapeutic strategies being developed against c-erbB-2.
  • To evaluate the safety and efficacy of these approaches in clinical trials.

Main Methods:

  • Review of existing literature on c-erbB-2 and immunotherapy.

Related Experiment Videos

  • Analysis of clinical trial data for c-erbB-2-targeted therapies.
  • Discussion of vaccination strategies (peptide, DNA, vector-based) and monoclonal antibody approaches.

    • Main Results:

    • c-erbB-2 p185 can elicit immune responses in cancer patients.
    • Immunotherapeutic approaches, including vaccines and monoclonal antibodies, are safe and feasible.
    • Clinical trials have demonstrated objective responses in some patients with advanced disease.

    Conclusions:

    • c-erbB-2 is a viable target for cancer immunotherapy.
    • Monoclonal antibodies offer multiple therapeutic functions.
    • Adjuvant immunotherapy in minimal residual disease settings may offer the greatest benefit.